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Summary
Background The post-2015 End TB Strategy proposes targets of 50% reduction in tuberculosis incidence and 75% 
reduction in mortality from tuberculosis by 2025. We aimed to assess whether these targets are feasible in three 
high-burden countries with contrasting epidemiology and previous programmatic achievements.
Methods 11 independently developed mathematical models of tuberculosis transmission projected the epidemiological 
impact of currently available tuberculosis interventions for prevention, diagnosis, and treatment in China, India, and 
South Africa. Models were calibrated with data on tuberculosis incidence and mortality in 2012. Representatives from 
national tuberculosis programmes and the advocacy community provided distinct country-speciﬁ c intervention 
scenarios, which included screening for symptoms, active case ﬁ nding, and preventive therapy.
Findings Aggressive scale-up of any single intervention scenario could not achieve the post-2015 End TB Strategy 
targets in any country. However, the models projected that, in the South Africa national tuberculosis programme 
scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral therapy, expanded 
facility-based screening for symptoms of tuberculosis at health centres, and improved tuberculosis care could achieve 
a 55% reduction in incidence (range 31–62%) and a 72% reduction in mortality (range 64–82%) compared with 2015 
levels. For India, and particularly for China, full scale-up of all interventions in tuberculosis-programme performance 
fell short of the 2025 targets, despite preventing a cumulative 3·4 million cases. The advocacy scenarios illustrated the 
high impact of detecting and treating latent tuberculosis.
Interpretation Major reductions in tuberculosis burden seem possible with current interventions. However, additional 
interventions, adapted to country-speciﬁ c tuberculosis epidemiology and health systems, are needed to reach the 
post-2015 End TB Strategy targets at country level.
Funding Bill & Melinda Gates Foundation. 
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Introduction
In May, 2014, the World Health Assembly approved the 
post-2015 End TB Strategy, setting “ambitious but 
feasible” targets for reducing the global burden of 
tuberculosis by 2035.1,2 The strategy is aiming for a 50% 
reduction in global tuberculosis incidence and a 75% 
reduction in global tuberculosis mortality by 2025, and 
90% and 95% reductions in these outcomes, respectively, 
by 2035.2 Policy makers must identify what interventions, 
and at which level of scale-up, will be needed to meet 
these targets at country level.
The End TB targets are deliberately ambitious, and any 
single intervention (deﬁ ned here as a group of activities 
leading to an improvement in a speciﬁ c area of tuberculosis 
control—eg, treatment outcomes) is unlikely to achieve 
these goals.3 Instead, national tuberculosis programmes 
will need improvements across the tuberculosis care 
pathway, together with preventive measures.
The End TB Strategy describes two phases of future 
eﬀ orts to control tuberculosis.2 In phase 1, the focus of 
this Article, progression towards the 2025 milestones 
will largely depend on optimising the use of existing 
tools, enabled by investments in universal health 
coverage and social protection.4 Post-2025 in phase 2, 
novel tools (diagnostics, drugs, and vaccines) are expected 
to enable further acceleration of tuberculosis decline 
towards the 2035 targets.1 For both phases of the End TB 
Strategy, policy makers require guidance about which 
interventions and technologies to use—questions that 
are unlikely to be answered by empirical studies, given 
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the diﬃ  culty of testing all possible approaches at high 
scale before policy decisions are made.
Mathematical modelling is a powerful tool to support 
policy discussions, because several hypothetical inter-
vention strategies can be compared in a systematic 
framework to project future trends.5–7 Multimodel exercises 
for HIV8,9 have illustrated how diﬀ erences in model design 
can inﬂ uence results, yet this structural variation is not 
apparent in a single-model analysis. By comparing answers 
to the same question using diﬀ erent models, we can 
identify ﬁ ndings robust enough to account for between-
model variation, and as such contribute to the evidence 
needed to commit the resources for national-level policy 
initiatives. The points where model projections diverge can 
signal important knowledge gaps to be addressed by future 
research. Paired with information on use of resources, 
projections of health impact also can be used to estimate 
the cost-eﬀ ectiveness of competing policy options and to 
design optimum policy portfolios, which is beyond the 
scope of this paper.
To provide results relevant to individual countries, 
modelled analyses should be consistent with existing 
evidence on local tuberculosis epidemiology (eg, incidence, 
mortality, prevalence, and multidrug-resistant [MDR] 
tuberculosis) and tuberculosis control activities (eg, 
treatment success, and linkage to care), and tailor 
intervention scenarios to local needs and capabilities. 
Because the required information is not always available 
in a systematic way in the public domain, involvement of 
local experts is key.
In this Article, we describe epidemiological pro-
jections from 11 independently developed dynamic 
transmission models of tuberculosis, exploring the 
feasibility of the 2025 End TB Strategy targets in China, 
India, and South Africa. These analyses explore a range 
of policy scenarios, incorporating perspectives from 
national tuberculosis programmes and advocacy 
communities. China, India, and South Africa account 
for approximately 40% of the global tuberculosis 
burden10 and are ideal to explore the feasibility of the 
targets in a country context because of their distinct 
combinations of epidemiological characteristics, health 
systems, and levels of tuberculosis prevention and care 
pathway activities. The likelihood of achieving the 
global targets will depend, to a large extent, on progress 
in these high-burden countries.
Research in context 
Evidence before this study
The post-2015 Global TB Strategy envisions and is aiming for 
a 50% reduction in tuberculosis incidence and a 75% reduction 
in tuberculosis mortality by 2025, using existing or near-existing 
tools. Given that this period starts in 2016, there is an urgent 
need to inform policy discussions on how these targets can be 
reached on a country level. Modelling can be a powerful tool to 
address this need by projecting the potential eﬀ ect of a 
combination of diﬀ erent interventions. Additionally, by using 
multiple models to address the same question, it can be used to 
identify ﬁ ndings robust to between-model variation, increasing 
conﬁ dence in the conclusions. We reviewed existing modelling 
studies that assessed the individual and combined impact of a 
range of existing interventions, and other multimodelling 
exercises in the ﬁ eld of tuberculosis. We built on a systematic 
review by the TB Modelling and Analysis Consortium who 
gathered all tuberculosis modelling papers and extended the 
review to June, 2015. PubMed was searched using the following 
search query: (tuberculosis OR TB) AND ((mathem* AND (model 
OR models)) OR (mathem* modell*) OR (mathem* modeling) 
OR (modeling OR modelling) OR “Population Dynamics” [MeSH 
Terms] OR “Population Dynamics” OR “System Dynamics” OR 
“Computer Simulation” OR “Computer Simulation” [MeSH 
Terms])”. We also did speciﬁ c searches in mathematical 
modelling journals, and searched private libraries, and 
references of existing modelling reviews. We only included 
English language papers and we used no date restrictions.
Ours is the ﬁ rst study to compare multiple tuberculosis models 
to answer a public health question. Single models have usually 
evaluated a single intervention, making it diﬃ  cult to understand 
the full potential, including potential synergy, or non-synergy, 
of a combination of interventions implemented simultaneously. 
Other multimodel exercises have been published, most notably 
in the ﬁ eld of HIV, which focused on questions around 
antiretroviral therapy scale-up to inform UNAIDS policy.
Added value of this study
This study highlights the uncertainty in the natural history of 
tuberculosis that drives between-model diﬀ erences, while still 
identifying relatively consistent ﬁ ndings of public health 
importance. It explores how a range of existing interventions 
across the tuberculosis care pathway, scaled up to 
country-speciﬁ c levels, can take China, India, and South Africa 
towards the 2025 global tuberculosis targets. Our results show 
that expansion of existing interventions should enable 
South Africa to reach the 2025 targets, while for India and China 
additional context-speciﬁ c activities are likely to be needed.
Implications of all the available evidence
Although major reductions in tuberculosis burden seem possible 
with current tools and 2025 targets might be met in South Africa, 
additional interventions, adapted to the country-speciﬁ c 
tuberculosis epidemiology and health systems, are likely to be 
needed to reach the post-2015 Global TB Targets in other key 
countries such as China and India. These might include 
interventions such as tackling the latent tuberculosis infection 
reservoir in elderly people in China and undernutrition in India. 
This decision making can be informed by rigorous data analysis 
and the logical framework that mathematical models provide.
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Methods
Participating models
After a global call from the TB Modelling and Analysis 
Consortium for expressions of interest, 11 modelling 
groups contributed results for at least one of the countries 
(China, India, or South Africa). These models varied 
in their frameworks, population stratiﬁ cations, and 
approaches used to model disease and intervention 
mechanisms. An overview of participating models and 
references is in table 1.
Data and country context for baseline
To calibrate the models and provide a baseline scenario, 
modellers were provided calibration targets reﬂ ecting 
tuberculosis burden (as incidence and mortality) in 
201211,12 and tuberculosis control activities. Because half 
the participating models only included adult groups 
(aged ≥15 years), calibration targets and results also 
focused on adults (appendix). For China, the calibration 
targets included 2000 and 2010 tuberculosis prevalence 
values as estimated by national surveys.13 For South Africa, 
models were calibrated to reﬂ ect an estimated 2–5% 
decline in the annual incidence of tuberculosis in 2012 
and projected scale-up of antiretroviral therapy (ART) 
coverage to 77% of HIV-positive adults by 202510,14 (see 
appendix section 1 for additional details of the calibration 
process, including sources).
Intervention scenarios
We deﬁ ned a framework of enhancements of tuberculosis-
programme activities using existing tools, which were 
grouped into intervention scenarios (ﬁ gure 1). Through 
detailed discussions with representatives from national 
tuberculosis programmes and the global advocacy 
community (Stop TB Partnership), we deﬁ ned two distinct 
levels of scale-up within those intervention scenarios. 
Table 2 summarises national tuberculosis programme 
and advocacy scenario sets for each country; see appendix 
seciton 2 for members and aﬃ  liations for each group.
The ﬁ rst intervention scenario looked at improvements 
in access to high-quality care, deﬁ ned as individuals with 
tuberculosis disease having access to the best level of 
care available in their local context. Tuberculosis care in 
China and India is provided through many health-care 
providers.15 Since the quality of care is known to diﬀ er 
strongly between providers,16,17 the intervention scenarios 
explored what could be achieved if a higher proportion of 
the population of patients with tuberculosis disease 
Preventive
therapy
(#5 and #6)
Active case
finding (#4)
Diagnostic tool
(#2)
Linkage to care 
(#3)
Improved
treatment
success (#3)
Active disease Accessed care Diagnosed Started 
treatment
Completed 
treatment
Access to high quality care (#1)
Figure 1: TB Care and Prevention framework
The patient care pathway from disease to completion of treatment (blue boxes and arrows). Areas aﬀ ected for 
enhancing current tuberculosis programme activities (ie, intervention scenarios) are shown in grey boxes and 
arrows, with the number (#x) to link them to activities in table 2 and the appendix section 3.
Country Model 
type
Model calibration Age structure Sex strata Population strata Results 
reported
Interventions 
modelled*
NTU31 China D Manual 15+ years No MDR, health-care sector, treatment history Single All
ICPHFI32 India D Algorithmic 15+ years No MDR, treatment history, HIV (2 strata), health-
care sector
Single All
STAMP33 India I Grid Search 1-month age groups Yes MDR, treatment history, health-care sector, 
time since infection and activation
Stoch All
Hopkins34 South Africa D Manual Single age group 
(15+ years)
No MDR, health-care sector, treatment history, 
HIV/ART/CD4 status (5 strata)
Single All
IRD35 South Africa D Manual 1-month age groups Yes (HIV only) HIV/ART/CD4 status (5 strata) Single IPT for ART
SIPTM South Africa D Manual <15, 15-19, 19< years No HIV/ART/CD4 status (5 strata) Single IPT for ART
UGA36 South Africa D Manual <15 and 15+ years No MDR, health-care sector, HIV/ART/CD4 (3 strata) Single All
IDM21 South Africa, 
China
I South Africa: Manual calibration 
China: Bayesian (incremental 
mixture importance sampling);
Explicit age No MDR, health-care sector, treatment history, 
HIV/ART/CD4
Stoch All
Harvard7 South Africa, 
India, China
D Bayesian Single age group No MDR, health-care sector, treatment history, 
HIV/ART/CD4 (9 strata)
Single All
AuTuMN37 South Africa, 
India, China
D Algorithmic <15 and 15+ years No MDR, health-care sector, South Africa: HIV/
ART/CD4 (5 strata)
Single All
TIME38 South Africa, 
India, China
D Manual <15 and 15+ years No MDR, treatment history HIV/ART/CD4 status 
(11 strata)
Single All
D=deterministic compartmental model. I=individual-based, stochastic model. Sex strata: Yes=natural history or care pathway parameters diﬀ erent for male and female patients; No=no sex stratiﬁ cation in 
models. MDR=multidrug-resistant. ART=antiretroviral therapy. Single=single parameter set. Stoch=average (mean or median) of stochastic simulations. *See table 2 for details of interventions.
Table 1: Description of mathematical models 
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China India South Africa
Activities* Base 
value 
Target value† Activities* Base 
value 
Target 
value
Activities* Base 
value
Target 
value
#1 Increase access to high quality care‡
Reduce proportion not accessing 
any tuberculosis care
Government subsidises 
tuberculosis care, and 
compensates patients for 
incurred costs 
5% 3·75%
(NTP), 0% (A)
Government subsidises 
diagnostic and treatment 
costs in private sector, 
expanding number of 
clinics and opening times 
of tuberculosis care 
9·5% 4·75% 
(NTP), 
0% (A)
Improve geographical access 
through outreach clinics
5% 0% 
(NTP), 
0% (A)
Of those with care access, 
increase proportion accessing 
high quality care
Same technology and 
approaches available in 
hospital and CDC sector 
80% 95% (NTP), 
100% (A)
Government subsidises 
use of high quality tools 
and protocols in private 
sector
50% 90% 
(NTP), 
100% (A)
Tuberculosis symptom 
screening for all health clinic 
attendees to ensure all in 
need receive tuberculosis 
diagnosis
20% 100% 
(NTP), 
100% (A)
#2 Diagnosis of disease and MDR§
Replace smear microscopy with 
molecular diagnostic (eg, 
GeneXpert) as ﬁ rst-line test
Replacement of smear 
microscopy with molecular 
diagnostic in facilities
0% 100% (NTP), 
100% (A)
Replacement of smear 
microscopy with molecular 
diagnostic in facilities
0% 30% 
(NTP), 
100% (A)
Not modelled because rollout 
of GeneXpert has been 
implemented already 
100% Not 
modelled
#3 Improve post-diagnosis care§
Reduce pretreatment loss to 
follow-up: ﬁ rst-line
Compensation for patient 
costs
3% 1·5% (NTP), 
0% (A)
Provide patient incentives 
for treatment initiation
10% 5% 
(NTP), 
0% (A)
Expand monitoring and 
assessment capacity, 
implement mhealth and 
outreach teams to trace 
patients in communities
17% 5% 
(NTP), 
0% (A)
Reduce pretreatment loss to 
follow-up: MDR
Compensation of patient 
costs, improvements in 
speed of diagnosis and 
referral
50% 15% (NTP), 
0% (A)
Linkage to social welfare 
programmes, including 
nutritional support
11% 5% 
(NTP), 
0% (A)
As above 50% 15% 
(NTP), 
0% (A)
Increase ﬁ rst-line treatment 
success
Implement patient 
support strategies 
including health and case 
management
82% 90% (NTP), 
95% (A)
Provide incentives and 
linkage to welfare 
programmes
75% 85% 
(NTP), 
90% (A)
Provide patient with 
adherence counselling and 
psychosocial support, as well 
as improved monitoring and 
evaluation
76% 85% 
(NTP), 
85% (A)
Increase MDR treatment success Improve patient 
monitoring (mhealth) 
and side-eﬀ ect 
amelioration
35% 65% (NTP), 
80% (A)
As above 48% 67% 
(NTP), 
80% (A)
All of above, as well as 
decentralisation of electronic 
register 
50% 67% 
(NTP), 
75% (A)
#4 Active case ﬁ nding in general population
Periodically screen a proportion 
of the general population for 
tuberculosis disease
As general description 0% 0% (NTP), 
30% (A)
As general description 0% 1·6% 
(NTP), 
30% (A)
As general description 0% 0% 
(NTP), 
50% (A)
#5 Active case ﬁ nding followed by treatment of latent tuberculosis
Provide LTBI screening and 
preventive therapy when positive 
to proportion of active case 
ﬁ nding population where active 
tuberculosis was excluded
As general description 0% 0% (NTP), 
100% (A)
As general description 0% 0% 
(NTP), 
100% (A)
As general description 0% 0% 
(NTP), 
100% (A)
#6 Continuous IPT for ART-receiving population 
Provide continuous IPT as part of 
ART in PLWHIV
Not modelled ·· ·· Not modelled ·· ·· Includes preinitiation 
screening, and rescreening of 
those lost to follow-up
5% 80% 
(NTP), 
100% (A)
#7 Combination 
Scale up all interventions 
simultaneously
All of above ·· ·· All of above ·· ·· All of above ·· ··
Information describes the general intervention eﬀ ects to be modelled, which were adapted to ﬁ t within speciﬁ c model structures (see appendix section 3 for details). Target value=absolute value. NTP=national 
tuberculosis programme scenario. A=advocacy scenario. PLWHIV=people living with HIV. CDC=Centers for Disease Control. mhealth=mobile health. MDR=multidrug resistant. LTBI=latent tuberculosis infection. 
IPT=isoniazid preventive treatment. ART=antretroviral therapy. *Summarises the activities proposed by the NTP scenario-setters to enhance current programme performance. †Scale-up to target value started in 
2016 and usually reached in 2020. ‡High quality care describes the best performing sector of all tuberculosis care providers—eg, public sector in India, CDC sector in China. §Intervention scenarios for diagnosis 
(#2) and care (#3) apply to population accessing high quality care only.
 Table 2: Summary of modelled intervention scenarios and target values for China, India, and South Africa
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received the higher quality care as provided in the 
Centers for Disease Control (China) or the public sector 
(India). For South Africa, models explored a new policy 
of expanded screening of health-centre visitors for 
symptoms of tuberculosis disease.
A second set of intervention scenarios modelled 
improvements in the tuberculosis care pathway, which 
included replacing sputum smears with a molecular 
diagnostic test such as GeneXpert as the ﬁ rst laboratory 
test, increasing linkage to care for individuals diagnosed 
with tuberculosis disease, and improved treatment 
outcomes for those linked to care. We also estimated the 
eﬀ ect of active case ﬁ nding for tuberculosis disease in 
the general population, implemented as simple screening 
of a proportion of the population for disease (table 2, 
appendix), either on its own, or as screening for active 
disease along with preventive therapy for individuals 
with latent tuberculosis infection. For South Africa, an 
additional intervention scenario estimated the impact of 
providing continuous isoniazid preventive therapy, with 
screening for active disease before initiation for 
individuals receiving ART. A combination intervention 
scenario estimated the overall impact of all interventions 
run simultaneously. Only models that contributed results 
to all individual interventions reported the combined 
intervention.
Under the advocacy scenarios, models estimated the 
potential eﬀ ect on tuberculosis incidence and mortality if 
countries were able to screen and treat 30% (India and 
China) or 50% (South Africa) of the general population 
(as a proxy for identifying a similar proportion of the 
burden through active-case ﬁ nding in high-risk groups) 
for tuberculosis disease and latent tuberculosis infection 
twice a year (table 2). With the exception of the active case 
ﬁ nding and preventive therapy for the general population, 
each intervention scenario was operationalised as speciﬁ c 
programmatic activities tailored to each country context 
(table 2). Modellers were asked to reﬂ ect these activities 
as closely as possible using their respective model 
structure and parameterisation (see appendix section 3 
for guidance provided and the implementation of the 
intervention scenarios for each model).
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Figure 2: Baseline calibration and projections for China, India, and South Africa
Y-axes scales have diﬀ erent values. Coloured lines show model results, black dots and lines show required calibration ranges. Additional calibration targets included 
prevalence surveys (China, 2000 and 2010) and 2–5% annual decline in incidence (South Africa). See appendix section 1 and 4 for details.
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Economic development and related investments in 
universal health coverage, components of Pillar 2 in the 
End TB Strategy1 were considered critical enablers of other 
intervention scenarios—eg, for access to high-quality care 
and treatment success (table 2, appendix section 3). Thus, 
we did not model separately potential beneﬁ ts for 
interventions such as achievement of universal health 
coverage, cash-transfer programmes, or the preventive 
eﬀ ect of poverty-reduction eﬀ orts on tuberculosis 
outcomes.
Models reported on tuberculosis incidence, mortality, 
and prevalence for the period 1990–2025. Because half 
the models captured adults only (table 1), our main 
outcomes were the change in adult (aged ≥15 years) 
incidence and mortality between 2015 and 2025 in 
the baseline scenarios. Additionally, we recorded the 
incremental impact of individual intervention scenarios 
and the overall impact of the baseline plus the 
combination intervention scenarios, and the cumulative 
cases and deaths averted. Additional outcomes reported 
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Figure 3: Impact of interventions on incidence for national tuberculosis programmes and advocacy scenarios
Figure shows the impact of baseline (left of dotted line) and incremental (excluding baseline, right of dotted line) impact of individual intervention scenarios (triangles and 
circles). Lines between models are for illustration of within-model impact of interventions. Models had to reﬂ ect the activities as provided by scenario setters (see table 2) as 
best as possible within their model framework, and provide an implementation narrative (see appendix section 3). Inevitably, simpliﬁ cation will have occurred to ﬁ t the 
intervention within the model structure. For example, in South Africa, the method of implementing the intervention scenario of isoniazid preventive therapy for HIV positive 
individuals receiving antiretroviral therapy will depend on whether the model had a separate compartment for isoniazid preventive therapy to track the number of individuals 
who were screened (as part of annual re-screening for tuberculosis) and have separate tuberculosis progression rates. See appendix section 3 for guidance and speciﬁ c 
implementation.
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by modellers included MDR tuberculosis prevalence in 
new or retreatment cases, latent tuberculosis infection 
prevalence, and the proportion of disease after recent 
infection. These outcomes were used to understand the 
diﬀ erences between models and ensure internal model 
consistency. After ﬁ tting to the calibration targets, 
modelling groups were provided with guidance on how 
to implement the intervention scenarios (appendix 
section 3) in view of the diﬀ erences in model structures. 
Additionally, we established minimum requirements to 
model structure for contribution to each scenario 
(appendix section 3).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
The modelling took place between March and December, 
2014. Of 11 participating models, six provided projections 
for China, ﬁ ve for India, and eight for South Africa. 
Three modelling groups (Harvard, AuTuMN and TIME) 
contributed results for all three countries and one model 
(IDM) modelled the China and South Africa epidemics. 
Of 11 models, nine provided results for all interventions 
(table 1).
Figure 2 shows baseline calibration and projections for 
incidence and mortality. In China, where models were 
calibrated to 2000 and 2010 prevalence targets (appendix 
sections 1 and 4), historical and projected trends were 
similar between models. For India, the historical 
uncertainty was propagated in the projections, although 
most models predicted a declining incidence trend 
consistent with recent WHO projections.10 In South Africa, 
models were calibrated to an epidemiological burden and 
trend in 2012, but diverged over time as the projected 
baseline change in incidence between 2015 and 2025 
ranged from 0 to 25%. For China and India, baseline 
changes in incidence were 11–27% and 0–19%, respectively, 
suggesting that with tuberculosis-programme activity, the 
tuberculosis burden was most likely to continue its decline.
In the national tuberculosis programme scenarios, the 
incremental contribution of individual intervention 
scenarios (compared with the baseline) diﬀ ered strongly 
between countries. In China, the additional impact of 
individual interventions on tuberculosis incidence and 
mortality was small for all scenarios (ﬁ gure 3, appendix 
section 4). By contrast, for India, improving access to 
high-quality care substantially reduced tuberculosis 
incidence beyond baseline trends by a median of 20% 
(range 5–41%). In the same setting, activities solely 
aimed at further improving care for patients already 
accessing high-quality care made little diﬀ erence to 
baseline trends. In South Africa, although we noted 
some between-model variation, most intervention 
scenarios showed substantial impact, with prevention 
(#6: continuous isoniazid preventive therapy for 
individuals receiving ART), case ﬁ nding (#1: screening at 
primary-health clinics), and improvements in linkage to 
care and treatment success (#3) reducing tuberculosis 
incidence by a further median of 16% (range 8–51%), 
20% (7–35%), and 8% (0–25%), respectively.
In South Africa, the 2025 End TB Strategy targets seem 
feasible, because the model projections showed that 
a combination of prevention, case ﬁ nding, and 
improvements in care (ﬁ gure 4) reduced incidence and 
mortality with a median of 55% (range 31–62%) and 72% 
(65–82%), respectively, and averted a cumulative 
1·2 million (0·7 million–1·8 million) cases of tuberculosis 
and 298 000 (193 000–453 000) deaths from tuberculosis 
between 2015 and 2025. In China, median cases and 
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Figure 4: Combination intervention impact on incidence and mortality in scnearios for national tuberculosis 
programmes (top row) and advocacy (bottom row)
Figure shows individual model impact (triangles and circles) and median impact (black bars). Dotted lines show 
2025 milestones of 50% reduction in incidence (left column) and 75% reduction in mortality (right column).
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achievement in tuberculosis control, but our results 
show that the targets and the tools enlisted to achieve 
them will need adapting to provide countries with a path 
that is both ambitious but also feasible. Achievement of 
the targets at a global level will be challenging, because 
more modest contributions from one country will need 
to be compensated by other countries going beyond these 
already highly ambitious targets. Additionally, for 
countries where the standard package of interventions is 
likely to be insuﬃ  cient, new strategies need to be 
developed that tackle country-speciﬁ c drivers, such as the 
ageing population of individuals with tuberculosis in 
China21 and high levels of undernutrition in India.22,23
As they stand, the advocacy scenarios would involve 
community-based tuberculosis screening for substantial 
parts of the population, twice a year. With current tools, 
this raises substantial issues around feasibility, resources, 
and evidence for impact.24 Also, we did not quantify 
potential negative eﬀ ects, including false-positive 
treatment, and regimen side-eﬀ ects. However, the 
advocacy scenarios illustrate a key point of addressing 
the latent tuberculosis infection reservoir in the 
population, particularly for settings like China where 
current high levels of tuberculosis programme 
performance (and resulting relatively minor contribution 
of transmission to tuberculosis incidence25) means 
substantial gains can be made in this area. Tools are 
needed to reduce the volume (and associated costs) of 
screening for active disease and treatment of latent 
tuberculosis infection, such as a postexposure vaccine, or 
a screening test that detects individuals with latent 
tuberculosis infection who are likely to progress in the 
next 5–10 years,26 all of which are part of Pillar 3 of the 
End TB strategy.1
We collated the best available data from published 
reports and country experts, but emphasise that improved 
information about tuberculosis epidemiology and the 
current tuberculosis care pathways is still needed. For 
example, substantial uncertainty exists about tuberculosis 
incidence and mortality in India, prevalence of latent 
tuberculosis infection, and treatment volume provided in 
public and private sectors, which can aﬀ ect model 
projections.10,15 The epidemiological eﬀ ect of activities 
often relied on expert opinion in the absence of reliable 
data, which adds uncertainty to model projections. 
Further evidence about eﬃ  cacy of interventions activities 
is needed to inform policy discussions at a global and 
national level.
In this project we aimed to examine the impact of major 
policy options in the tuberculosis response. As such, some 
speciﬁ c interventions that might be considered for speciﬁ c 
settings were not included such as addressing under-
nutrition in India and age-speciﬁ c screening for latent 
tuberculosis infection in China, which have been explored 
in other models. 21–23 Also, we did not include scenarios that 
focused on active case ﬁ nding in high-risk groups, such as 
miners or people living in informal settlements. To 
deaths averted by the combination intervention scenarios 
were 312 000 (range 42 000–764 000) cases of tuberculosis 
and 65 000 (10 000–93 000) deaths from tuberculosis. 
In India the corresponding ﬁ gures were 3·1 million 
(1·2 million–5·8 million) cases of tuberculosis and 
1·1 million (0·8 million–2·1 million) deaths from 
tuberculosis. Despite these projected substantial health 
gains, the proportional reductions between 2015 and 
2025 were estimated to fall short of the post-2015 End TB 
Strategy targets for China and India (ﬁ gure 4).
The impact of annual screening for active disease 
(#4 active-case ﬁ nding in the general population) was small 
when compared with the eﬀ ect of treating latent tuberculosis 
infection, particularly for China where #5 (active-case 
ﬁ nding followed by treatment of latent tuberculosis 
infection) achieved a median of 64% (range 52–81%) 
reduction in tuberculosis incidence (ﬁ gure 3), and the 
impact of the combined intervention exceeded the 2025 
global targets.
Discussion
Using multiple, independently developed tuberculosis 
transmission models, we explored the feasibility of 
achieving the post-2015 End TB Strategy targets in three 
high-burden countries, each with diﬀ erent epidemiology 
and existing levels of tuberculosis control. By projecting 
the impact of combinations of existing tools in China, 
India, and South Africa, we showed the importance of 
country context in assessing whether and how these 
global targets might be achieved at a country level. For 
South Africa, the 2025 milestones of 50% reduction in 
incidence and 75% reduction in mortality appear feasible 
with existing tools, whereas for India and China, these 
targets appear unfeasible.
Contrasting results between countries reﬂ ect the 
diﬀ erences between epidemiological context and 
responses of local tuberculosis epidemics. Whereas in 
China, two decades of steady improvement in reach and 
quality of basic tuberculosis services have led to nearly a 
two-thirds reduction in tuberculosis prevalence between 
1990 and 2010,13 South Africa’s tuberculosis programme 
was overwhelmed by the eﬀ ects of HIV,18 and is only just 
turning a corner.10,19 The room for further improvement 
with current tools diﬀ ers widely between countries, 
which leaves high-performing tuberculosis programmes, 
such as the one in China, with the question of how to 
achieve additional reductions. India faces speciﬁ c 
challenges around private providers of tuberculosis care, 
who are common throughout the southeast Asia region, 
and our results show that improving the quality of 
tuberculosis care in the private sector is essential. This 
process is underway, partly through an expansion of 
government subsidies to pay for individuals to access 
eﬀ ective tuberculosis diagnosis and treatment through 
the private sector.20
The post-2015 End TB Strategy targets are laudable in 
their ambition, and describe what would be a great 
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adequately capture these dynamics, and the impact of 
targeted interventions in these populations in a reasonable 
way, we believe that epidemiological models require 
speciﬁ c model structure, and credible data on size and 
tuberculosis burden in each population, as well as a 
reasonable estimate of mixing within and between the 
general and high-risk populations. When more data 
become available, these choices can be revisited.
We did not report parametric uncertainty, or the 
relationship between model structure and predicted 
outcomes. These issues represent areas for future 
research. What is clear is that, as models aim to capture 
greater complexity, the structural and parametric 
uncertainty that can be expressed increases. One 
illustration is the more pronounced divergence in 
baseline model projections for South Africa where HIV 
is a key driver of the tuberculosis burden. Models that 
capture the interaction between tuberculosis and HIV 
and the eﬀ ect of ART create additional opportunities for 
model diﬀ erences and resulting divergence of baseline 
projections. However, since there is no one true model 
structure, multimodel exercises such as ours are 
important to identify ﬁ ndings robust to the structural 
uncertainty, as we have here.
Our study provides unique insights on the feasibility of 
these global epidemiological 2025 targets at the country 
level, and illustrates the challenges ahead. In further 
work, these epidemiological projections have been linked 
to costs39 to explore cost-eﬀ ectiveness, aﬀ ordability, and 
poverty alleviation. Such information is vital as policy 
makers and the global tuberculosis community assess 
the health gains and economic costs that would come 
with scaling up existing tools to meet the ﬁ rst targets of 
the End TB Strategy.
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